Company: RGBP
Filing Date: 2025-12-05
Form Type: 253G1
Source: 0001493152-25-026350
Chunk: 155

Company: Regen BioPharma Inc
Filing Date: 2025-12-05
Form: 253G1
Chunk 155
---
 in connection with the issuance of a promissory 
 note in the face amount of $250,000                                                                                                   |
| ● | On                                                                                                                                    
 September 26,2024 the Company issued 249,915 shares as consideration for nonemployee services.                                        |

<div align='center'>116</div>

14. INCOME TAXES

As of September 30, 2024

| Deferred tax assets:             |     |   |            |   |
|:---------------------------------|:----|:--|-----------:|:--|
| Net operating tax carry forwards |     | $ |  4,287,595 |   |
| Other                            |     |   |          - |   |
| Gross deferred tax assets        |     |   |  4,287,595 |   |
| Valuation allowance              |     |   | (4,287,595 | ) |
| Net deferred tax assets          |     | $ |          - |   |

NOTE 10. INCOME TAXES

As of September 30, 2023

| Deferred tax assets:             |     |   |            |   |
|:---------------------------------|:----|:--|-----------:|:--|
| Net operating tax carry forwards |     | $ |  4,147,261 |   |
| Other                            |     |   |         (0 | ) |
| Gross deferred tax assets        |     |   |  4,147,261 |   |
| Valuation allowance              |     |   | (4,147,261 | ) |
| Net deferred tax assets          |     | $ |         (0 | ) |

As of September 30 2024 the Company has a Deferred Tax Asset of $4,287,595 completely attributable to net operating loss carry forwards of approximately $20,417,118. The amount and availability of any net operating loss carryforward will be subject to the limitations set forth in the Internal Revenue Code. Such factors as the number of shares ultimately issued within a three-year look-back period; whether there is a deemed more than 50% change in control; the applicable long-term tax exempt bond rate; continuity of historical business; and subsequent income of the Company all enter into the annual computation of allowable annual utilization of any net operating loss carryforward.

As of September 30 2023 the Company has a Deferred Tax Asset of $4,147,261 completely attributable to net operating loss carry forwards of approximately $19,